IL10 and rheumatoid arthritis: Still considering the traditional treatments for RA, methotrexate (MTX), a first-line DMARD in the pharmacological management of RA [30], induced the secretion of IL-10, an anti-inflammatory cytokine, inhibited the production of ·NO and increased ROS generation in active RA patients [27].